References
- Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int .1 Cancer 1997; 72: 1–22.
- Ossowski L. In vivo invasion of modified chorioallan-toic membrane by tumour cells: the role of surface-bound urokinase. J Cell Biol 1988; 107: 2437–45.
- Crowley CW, Cohen RL, Lucas BK, Liu BK, Shuman MA, Levinson AD. Prevention of metastasis by in-hibiton of the urokinase receptor. Proc Natl Acad Sci 1993; 90: 5021–5.
- Ronne E, Pappot H, Grondahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol 1995; 89: 576–81.
- Pappot H, Hoyer-Hansen G, Ronne E, et al. Elevated plasma levels or urokinase plasminogen activator receptor in Non-small cell lung cancer patients. Eur J Cancer 1997; 33: 867–72.
- Sier CFM, Stephens R, Bizik J, et al. The level of urokinase-type plasminogen activator receptor is in-creased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843–9.
- Schmalfeldt B, Kuhn W, Reuning U, et al. Primary tumour and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995; 55: 3958–63.
- Graham CH, Forsdike J, Fitzgerald CJ, Mcdonald-Goodfellow S. Hypoxia-mediated stimulation of car-cinoma cell invasiveness via up-regulation of urokinase receptor expression. Int .1 Cancer 1999; 80: 617–23.
- Brizel DM, Sibley GS, Prosnitz LR, Scher RL, De-whirst MW. Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int .1 Rad Oncol Biol Phys 1997; 38: 285–9.
- Ploug M, Eriksen J, Plesner T, Hansen NE, Dano K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with parox-ysmal nocturnal hemoglobinuria. Eur J Biochem 1992; 208: 397–404.
- Ho CH, Chau WK, Chao Y, et al. Diagnostic and prognostic value of plasma fibrinolytic markers in hep-atocellular carcinoma. Adv Ther 1998; 15: 98–105.
- Stephens RW, Nielen HJ, Christensen IJ, et al. Plasma urokinase levels in patients with colorectal cancer: rela-tionship to prognosis. J Natl Cancer Inst 1999; 91: 869–74.
- Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int .1 Cancer 1995; 60: 501–6.
- Plebani M, Herszeny L, Carraro P, et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metas-tasis 1997; 15: 418–25.
- Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plas-minogen activator inhibitor type I (PAT-I) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 1998; 34: 1193–7.